Trial Outcomes & Findings for Pediatric Reporting of Adult-Onset Genomic Results (NCT NCT03832985)
NCT ID: NCT03832985
Last Updated: 2026-04-09
Results Overview
The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).
COMPLETED
EARLY_PHASE1
162 participants
Baseline
2026-04-09
Participant Flow
Results reporting is primarily focused on the parent participants who completed data collection, though we now report adolescents' results for primary outcomes. Analysis sample includes parent participants who completed all data collection. Nearly half of consenting parents could not be reached to complete surveys at T2, T3 or T4.
Parents were assigned to a group once their child(ren) received genetic test results. Group 1 comprised parents whose child (or all tested children) had an adult-onset genetic result. Group 2 comprised parents whose child (or all tested children) had a pediatric-onset genetic result. Group 3 comprised parents who child (or all tested children) tested negative for the familial genetic variant. Groups 4-6 are adolescents who corresponded to the parent groups.
Participant milestones
| Measure |
Group 1 (Parents of Child(Ren) With Adult-onset Result)
Parents of child(ren) with adult-onset result
|
Group 2 (Parents of Child(Ren) With Pediatric-onset Result)
Parents of child(ren) with pediatric-onset result
|
Group 3 (Parents of Child(Ren) Who Tested Negative for Familial Variant)
Parents of child(ren) negative for familial genetic variant
|
Group 4 (Adolescent With Adult-onset Result)
Adolescents with an adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
Adolescents with pediatric-onset genetic variant
|
Group 6 (Adolescents Who Tested Negative for Familial Variant)
Adolescents who tested negative for familial genetic variant
|
|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
21
|
36
|
35
|
15
|
20
|
35
|
|
Overall Study
COMPLETED
|
13
|
18
|
20
|
4
|
13
|
23
|
|
Overall Study
NOT COMPLETED
|
8
|
18
|
15
|
11
|
7
|
12
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Added row for adolescents to separate mean (SD) ages for parents and adolescents
Baseline characteristics by cohort
| Measure |
Group 2 (Parents of Children With Pediatric-onset Result)
n=36 Participants
Parents of child(ren) with pediatric-onset result
|
Group 3 (Parents of Child(Ren) Who Tested Negative for Familial Variant)
n=35 Participants
Parents of child(ren) negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=15 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=20 Participants
Adolescents with pediatric-onset genetic variant
|
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
|
Total
n=162 Participants
Total of all reporting groups
|
Group 1 (Parents of Child(Ren) With Adult-onset Result)
n=21 Participants
Parents of child(ren) with adult-onset result
|
|---|---|---|---|---|---|---|---|
|
Age, Continuous
Parents
|
38.1 year-old
STANDARD_DEVIATION 8.2 • n=36 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
40 year-old
STANDARD_DEVIATION 9.6 • n=35 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
—
|
—
|
—
|
39.6 year-old
STANDARD_DEVIATION 8.6 • n=92 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
39.5 year-old
STANDARD_DEVIATION 7.6 • n=21 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
|
Age, Continuous
Adolescents
|
—
|
—
|
14.42 year-old
STANDARD_DEVIATION 2.11 • n=15 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
13.85 year-old
STANDARD_DEVIATION 2.56 • n=20 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
14.39 year-old
STANDARD_DEVIATION 2.03 • n=35 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
14.24 year-old
STANDARD_DEVIATION 2.19 • n=70 Participants • Added row for adolescents to separate mean (SD) ages for parents and adolescents
|
—
|
|
Sex: Female, Male
Female
|
30 Participants
n=36 Participants
|
29 Participants
n=35 Participants
|
9 Participants
n=15 Participants
|
12 Participants
n=20 Participants
|
12 Participants
n=35 Participants
|
110 Participants
n=162 Participants
|
18 Participants
n=21 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=36 Participants
|
6 Participants
n=35 Participants
|
6 Participants
n=15 Participants
|
8 Participants
n=20 Participants
|
23 Participants
n=35 Participants
|
52 Participants
n=162 Participants
|
3 Participants
n=21 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=36 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=162 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=36 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=162 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=36 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=162 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=36 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=15 Participants
|
1 Participants
n=20 Participants
|
1 Participants
n=35 Participants
|
4 Participants
n=162 Participants
|
1 Participants
n=21 Participants
|
|
Race (NIH/OMB)
White
|
32 Participants
n=36 Participants
|
32 Participants
n=35 Participants
|
15 Participants
n=15 Participants
|
16 Participants
n=20 Participants
|
26 Participants
n=35 Participants
|
141 Participants
n=162 Participants
|
20 Participants
n=21 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=36 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=15 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=162 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
3 Participants
n=36 Participants
|
3 Participants
n=35 Participants
|
0 Participants
n=15 Participants
|
3 Participants
n=20 Participants
|
8 Participants
n=35 Participants
|
17 Participants
n=162 Participants
|
0 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
2 Participants
n=36 Participants
|
1 Participants
n=35 Participants
|
2 Participants
n=15 Participants
|
1 Participants
n=20 Participants
|
2 Participants
n=35 Participants
|
9 Participants
n=162 Participants
|
1 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
33 Participants
n=36 Participants
|
34 Participants
n=35 Participants
|
13 Participants
n=15 Participants
|
16 Participants
n=20 Participants
|
25 Participants
n=35 Participants
|
140 Participants
n=162 Participants
|
19 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=36 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=15 Participants
|
3 Participants
n=20 Participants
|
8 Participants
n=35 Participants
|
13 Participants
n=162 Participants
|
1 Participants
n=21 Participants
|
PRIMARY outcome
Timeframe: BaselinePopulation: Participants who have completed the survey at each follow-up time.
The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=21 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=36 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
|
8.96 units on scale
Standard Deviation 3.10
|
10.32 units on scale
Standard Deviation 3.68
|
8.26 units on scale
Standard Deviation 3.33
|
PRIMARY outcome
Timeframe: BaselinePopulation: Participants who have completed the survey at each follow-up time.
The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=21 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=36 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
|
6.33 units on scale
Standard Deviation 2.4
|
6.79 units on scale
Standard Deviation 2.4
|
6.61 units on scale
Standard Deviation 2.65
|
PRIMARY outcome
Timeframe: BaselinePopulation: Participants who have completed the survey at each follow-up time.
The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=16 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=25 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
|
1.7 units of scale
Standard Deviation 0.6
|
1.7 units of scale
Standard Deviation 0.4
|
1.5 units of scale
Standard Deviation 0.5
|
PRIMARY outcome
Timeframe: BaselinePopulation: Collapse score 4-5 to 'Fair to Poor'
Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=21 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=36 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
6 Participants
|
3 Participants
|
8 Participants
|
PRIMARY outcome
Timeframe: 6+ months post-disclosure to pediatric probandPopulation: Analysis only conducted for participants with a pathogenic/likely pathogenic variant in gene of interest (children who tested negative for a relevant genetic variant were not evaluated for initiation of risk reduction procedures). Children of all ages were included in the analysis.
Initiation of risk reduction behavior (yes/no) among children with familial gene variant. Not that this is among children of all ages (not just adolescents). Counts are of participants who initiated a risk reduction behavior. Data were collected via chart review for pre-selected risk reduction procedures specific to each genetic condition. Time in months from results disclosure date to date of risk reduction behavior was tracked.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=34 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=31 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Initiation of Risk Reduction Behavior
|
—
|
0 Participants
|
13 Participants
|
PRIMARY outcome
Timeframe: 1-month post-disclosureThe HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases.Total range is 0 (lowest anxiety) - 21 (most severe anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
|
6.1 units of scale
Standard Deviation 3.91
|
10.29 units of scale
Standard Deviation 3.43
|
5.17 units of scale
Standard Deviation 3.92
|
PRIMARY outcome
Timeframe: 6-month post-disclosureThe HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=12 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
|
5.98 units of scale
Standard Deviation 3.66
|
10.74 units of scale
Standard Deviation 4.29
|
5.6 units of scale
Standard Deviation 4.11
|
PRIMARY outcome
Timeframe: 12-month post-disclosureThe HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest anxiety) - 21 (most severe anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=10 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=16 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale
|
5.5 units of scale
Standard Deviation 3.29
|
8.9 units of scale
Standard Deviation 4.61
|
6.12 units of scale
Standard Deviation 4.05
|
PRIMARY outcome
Timeframe: 1-month post-disclosurePopulation: Participants who have completed the survey at each follow-up time.
The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
|
3.5 units of scale
Standard Deviation 3.12
|
5.64 units of scale
Standard Deviation 4.67
|
2.26 units of scale
Standard Deviation 2.54
|
PRIMARY outcome
Timeframe: 6-month post-disclosurePopulation: Participants who have completed the survey at each follow-up time.
The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=12 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
|
3.33 units of scale
Standard Deviation 3.09
|
5.0 units of scale
Standard Deviation 3.88
|
3.42 units of scale
Standard Deviation 3.16
|
PRIMARY outcome
Timeframe: 12-month postPopulation: Participants who have completed the survey at each follow-up time.
The HADS questionnaire is a 14-item scale comprised of seven questions for anxiety and seven questions for depression. Each item is scored from 0-3. The total scoring is as follows: 8-10 = Mild, 11-14 = Moderate, 15-21 = Severe. Scoring for anxiety and depression are to be completed separately. For both scales, a total score of less than 7 indicates non-cases. Total range is 0 (lowest) - 21 (most severe).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=10 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=16 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The Hospital Anxiety and Depression Scale (HADS) - Depression Subscale
|
2.39 units of scale
Standard Deviation 2.39
|
4.4 units of scale
Standard Deviation 3.66
|
3.31 units of scale
Standard Deviation 3.66
|
PRIMARY outcome
Timeframe: 1-month postPopulation: Participants who have completed the survey at each follow-up time.
The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=21 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=7 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
|
1.7 units of scale
Standard Deviation 0.4
|
1.9 units of scale
Standard Deviation 0.4
|
1.3 units of scale
Standard Deviation 0.4
|
PRIMARY outcome
Timeframe: 6-month postPopulation: Participants who have completed the survey at each follow-up time.
The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=8 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
|
1.7 units of scale
Standard Deviation 0.5
|
1.8 units of scale
Standard Deviation 0.5
|
1.5 units of scale
Standard Deviation 0.4
|
PRIMARY outcome
Timeframe: 12-month postPopulation: Participants who have completed the survey at each follow-up time.
The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=24 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=17 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
The General Functioning 12-item Subscale (GF12) of The McMaster Family Assessment Device (FAD)
|
1.6 units of scale
Standard Deviation 0.5
|
1.5 units of scale
Standard Deviation 0.4
|
1.4 units of scale
Standard Deviation 0.4
|
PRIMARY outcome
Timeframe: 1-month postPopulation: Collapse score 4-5 to report 'Fair to Poor'
Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
4 Participants
|
1 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: 6-month postPopulation: Collapse score 4-5 to 'Fair to Poor'
Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=27 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=12 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
2 Participants
|
1 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: 12-month postPopulation: Collapse score 4-5 to 'Fair to Poor'
Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=14 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=21 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
4 Participants
|
3 Participants
|
4 Participants
|
PRIMARY outcome
Timeframe: baselineAnxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=25 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=9 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=11 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
|
44.94 T-score
Standard Deviation 12.17
|
57.23 T-score
Standard Deviation 17.08
|
40.78 T-score
Standard Deviation 9.51
|
PRIMARY outcome
Timeframe: 1-month (T2)Anxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=17 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=3 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
|
39.45 T-score
Standard Deviation 10.25
|
45.83 T-score
Standard Deviation 7.08
|
45.12 T-score
Standard Deviation 21.28
|
PRIMARY outcome
Timeframe: 6-month (T3)Anxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=2 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=7 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
|
44.08 T-score
Standard Deviation 13.55
|
41.44 T-score
Standard Deviation 13.06
|
37.90 T-score
Standard Deviation 7.11
|
PRIMARY outcome
Timeframe: 12-month (T4)Anxiety subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher anxiety).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=1 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Anxiety Subscale
|
35.86 T-score
Standard Deviation 10.28
|
56.85 T-score
Standard Deviation NA
SD not applicable for single participant
|
44.24 T-score
Standard Deviation 11.20
|
PRIMARY outcome
Timeframe: BaselineDepression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=25 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=9 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=11 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Depression Subscale
|
47.46 T-score
Standard Deviation 15.69
|
59.25 T-score
Standard Deviation 14.03
|
42.29 T-score
Standard Deviation 11.61
|
PRIMARY outcome
Timeframe: 1-month (T2)Depression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=17 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=3 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Depression Subscale
|
41.04 T-score
Standard Deviation 13.63
|
48.08 T-score
Standard Deviation 11.85
|
45.68 T-score
Standard Deviation 17.80
|
PRIMARY outcome
Timeframe: 6-month (T3)Depression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=2 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=7 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Depression Subscale
|
47.02 T-score
Standard Deviation 17.86
|
51.00 T-score
Standard Deviation 26.79
|
38.98 T-score
Standard Deviation 7.47
|
PRIMARY outcome
Timeframe: 12-month (T4)Depression subscale of the brief (25-item) version of Revised Children's Anxiety and Depression Scale. Items are scored from 0 (never) to 3 (always) and cumulative scores are converted to T scores per measure guidelines based on participants' school grade and sex. RCADS raw scores were converted to age- and sex-normed T-scores, where a T-score of 48 represents the population mean and the standard deviation is 14 at baseline. T score of greater than or equal to 70 exceeds the clinical threshold (i.e., higher T score = higher depression).
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=14 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=1 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=8 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Revised Children's Anxiety and Depression Scale - Depression Subscale
|
36.75 T-score
Standard Deviation 9.01
|
70.55 T-score
Standard Deviation NA
SD not applicable for single participant
|
44.36 T-score
Standard Deviation 10.87
|
PRIMARY outcome
Timeframe: baselineThe GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=15 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=20 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
|
1.88 units of scale
Standard Deviation 0.60
|
1.90 units of scale
Standard Deviation 0.58
|
1.78 units of scale
Standard Deviation 0.52
|
PRIMARY outcome
Timeframe: 1-month (T2)The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=6 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
|
1.80 units of scale
Standard Deviation 0.66
|
2.06 units of scale
Standard Deviation 0.46
|
1.56 units of scale
Standard Deviation 0.45
|
PRIMARY outcome
Timeframe: 6-month (T2)The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=25 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=5 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=12 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
|
1.84 units of scale
Standard Deviation 0.61
|
1.92 units of scale
Standard Deviation 0.38
|
1.60 units of scale
Standard Deviation 0.44
|
PRIMARY outcome
Timeframe: 12-month (T2)The GF12 subscale is made up of 12 items, six items that reflect healthy family functioning and the other six items reflecting unhealthy functioning. Scoring is on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items reversed. The total score is then divided by the number of items on the subscale giving a total score ranging from 1.0 (best functioning) to 4.0 (worse functioning)
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=4 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=13 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
General Functioning 12-item Subscale (GF12) of the McMaster Family Assessment Device (FAD)
|
1.82 units of scale
Standard Deviation 0.72
|
1.71 units of scale
Standard Deviation 0.73
|
1.70 units of scale
Standard Deviation 0.47
|
PRIMARY outcome
Timeframe: BaselineHealthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=35 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=15 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=20 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
0 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: 1-month (T2)Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=28 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=6 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=15 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
1 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: 6-month (T3)Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=24 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=5 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=12 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
2 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: 12-month (T3)Healthy days are the positive complementary form of unhealthy days. Healthy days estimates the number of recent days when a person's physical and mental health was good (or better) and is calculated by subtracting the number of unhealthy days from 30 days. Unhealthy days are an estimate of the overall number of days during the previous 30 days when the respondent felt that either his or her physical or mental health was not good. To obtain this estimate, responses to questions 2 and 3 are combined to calculate a summary index of overall unhealthy days, with a logical maximum of 30 unhealthy days. For example, a person who reports 4 physically unhealthy days and 2 mentally unhealthy days is assigned a value of 6 unhealthy days, and someone who reports 30 physically unhealthy days and 30 mentally unhealthy days is assigned the maximum of 30 unhealthy days. Here we report the number and % of participants who reported fair or poor HRQoL.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=23 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=4 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=13 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Health-Related Quality of Life (HRQOL)
|
1 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 1- month post-disclosurePopulation: Participants who have completed the survey at each follow-up time.
The Decision Regret Scale is made up of 5 items that address the notion of regret in a variety of ways. Scoring on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items. The total score is taken from the mean of the 5 items, and then converted to a 0-100 scale by subtracting 1 from each item then multiply by 25. A score of 0 means no regret; a score of 100 means high regret.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Decision Regret Scale
|
8.0 units of scale
Standard Deviation 14.8
|
15.9 units of scale
Standard Deviation 13.9
|
7.4 units of scale
Standard Deviation 12.2
|
SECONDARY outcome
Timeframe: 12- month post-disclosurePopulation: Participants who have completed the survey at each follow-up time.
The Decision Regret Scale is made up of 5 items that address the notion of regret in a variety of ways. Scoring on a 4-point scale (from 1 for strongly agree to 4 for strongly disagree) with the scale for the negatively worded items. The total score is taken from the mean of the 5 items, and then converted to a 0-100 scale by subtracting 1 from each item then multiply by 25. A score of 0 means no regret; a score of 100 means high regret.
Outcome measures
| Measure |
Group 6 (Adolescents Who Tested Negative for Familial Variant)
n=30 Participants
Adolescents who tested negative for familial genetic variant
|
Group 4 (Adolescents With Adult-onset Result)
n=11 Participants
Adolescents with adult-onset genetic variant
|
Group 5 (Adolescents With Pediatric-onset Result)
n=19 Participants
Adolescents with pediatric-onset genetic variant
|
|---|---|---|---|
|
Decision Regret Scale
|
5.9 units of scale
Standard Deviation 13.9
|
7.7 units of scale
Standard Deviation 10.8
|
8.1 units of scale
Standard Deviation 11.6
|
Adverse Events
Group 1 (Parents of Child(Ren) With Adult-onset Result)
Group 2 (Parents of Child(Ren) With Pediatric-onset Result)
Group 3 (Parents of Child(Ren) Who Tested Negative for Familial Variant)
Group 4 (Adolescents With Adult-onset Result)
Group 5 (Adolescents With Pediatric-onset Result)
Group 6 (Adolescents Who Tested Negative for Familial Variant)
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place